The Glee alum welcomed baby Emery in August with husband Zandy Reich (they also share 4-year-old son Ever). Michele shared a ...

A rising U.S. dollar could cause trouble for stock-market bulls Stock-market investors will want to keep a nervous eye on the U.S. dollar, as history shows continued strength for the currency ...

The Dow Jones Industrial Average was also in the green. The 30-stock index outpaced its peers in November with a 7.5% surge, capped off by a 0.4% jump Friday that took it close to 44,910 points.

On Thursday, the “Pulp Fiction” star’s daughters, Tallulah and Scout Willis, posted adorable photos on Instagram of them gifting their dad a desk nameplate ... At HuffPost, we believe journalism ...

RateGain Travel Technologies Limited announced today that Vietjet Thailand has partnered with AirGain, the company’s pricing intelligence platform, to enhance its market positioning in the low ...

When Elon Musk posts to X, his 206 million followers, powerful people including President-elect Donald Trump, and the stock market listen ... likely still keeping an eye on Musk's activity ...

Human beings are complex creatures. And many media pundits don't seem to understand a basic truth: How a person feels doesn't need to make sense. I'm not here to plant my flag in the debate ...

Photo by Amanda Dalbjörn on Unsplash. "ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start ...

Outlook Therapeutics plans to resubmit the U.S. marketing application for ONS-5010 in the first quarter of calendar 2025. Outlook Therapeutics intends to continue efforts to launch in Europe in ...

OTLK stock is down 80% at $0.97 during the premarket session at last check Wednesday. Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the failure, noting positive details and vowing to seek FDA approval ...

They both trade at about 3 times sales compared to 28 times sales for The Trade Desk stock. With such low valuations, it doesn't seem like investors expect much from Roku or PubMatic in the near ...